IL286727A - fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma - Google Patents
fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinomaInfo
- Publication number
- IL286727A IL286727A IL286727A IL28672721A IL286727A IL 286727 A IL286727 A IL 286727A IL 286727 A IL286727 A IL 286727A IL 28672721 A IL28672721 A IL 28672721A IL 286727 A IL286727 A IL 286727A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- tyrosine kinase
- kinase inhibitors
- urothelial carcinoma
- fgfr tyrosine
- Prior art date
Links
- 206010044412 transitional cell carcinoma Diseases 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 208000023747 urothelial carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166429 | 2019-03-29 | ||
| US201962833395P | 2019-04-12 | 2019-04-12 | |
| PCT/EP2020/058814 WO2020201138A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286727A true IL286727A (en) | 2021-10-31 |
Family
ID=69954076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286727A IL286727A (en) | 2019-03-29 | 2021-09-26 | fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220175768A1 (https=) |
| EP (2) | EP4548935A3 (https=) |
| JP (2) | JP2022527482A (https=) |
| KR (1) | KR20210143878A (https=) |
| CN (1) | CN113645975A (https=) |
| AU (1) | AU2020253054B2 (https=) |
| BR (1) | BR112021019203A2 (https=) |
| CA (1) | CA3130773A1 (https=) |
| IL (1) | IL286727A (https=) |
| JO (1) | JOP20210260A1 (https=) |
| MA (1) | MA55486A (https=) |
| MX (1) | MX2021011943A (https=) |
| PH (1) | PH12021552352A1 (https=) |
| SG (1) | SG11202109854RA (https=) |
| WO (1) | WO2020201138A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002980A (es) * | 2020-09-14 | 2023-06-06 | Janssen Pharmaceutica Nv | Terapias de combinación de inhibidores del fgfr. |
| KR20240019293A (ko) * | 2021-06-07 | 2024-02-14 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 습기 감응성 약학 조성물용 보호 코팅 |
| EP4415692A1 (en) | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Erdafitinib formulations and systems for intravesical administration |
| CN119072311A (zh) | 2022-02-18 | 2024-12-03 | 塔里斯生物医药公司 | 用于膀胱内施用的厄达替尼制剂和渗透系统 |
| CN116106240B (zh) * | 2022-12-26 | 2025-11-07 | 华中农业大学 | 一种尿液酪氨酸检测体系、检测方法及检测试剂盒 |
| CN120731076A (zh) | 2023-02-13 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
| JP2026506041A (ja) | 2023-02-17 | 2026-02-20 | タリス バイオメディカル エルエルシー | 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| EP4063516A1 (en) | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-03-27 SG SG11202109854R patent/SG11202109854RA/en unknown
- 2020-03-27 US US17/598,985 patent/US20220175768A1/en active Pending
- 2020-03-27 EP EP24174999.3A patent/EP4548935A3/en active Pending
- 2020-03-27 AU AU2020253054A patent/AU2020253054B2/en active Active
- 2020-03-27 MA MA055486A patent/MA55486A/fr unknown
- 2020-03-27 CN CN202080026737.4A patent/CN113645975A/zh active Pending
- 2020-03-27 MX MX2021011943A patent/MX2021011943A/es unknown
- 2020-03-27 PH PH1/2021/552352A patent/PH12021552352A1/en unknown
- 2020-03-27 BR BR112021019203A patent/BR112021019203A2/pt unknown
- 2020-03-27 WO PCT/EP2020/058814 patent/WO2020201138A1/en not_active Ceased
- 2020-03-27 KR KR1020217034729A patent/KR20210143878A/ko not_active Ceased
- 2020-03-27 CA CA3130773A patent/CA3130773A1/en active Pending
- 2020-03-27 JP JP2021557790A patent/JP2022527482A/ja active Pending
- 2020-03-27 EP EP20713656.5A patent/EP3946340A1/en active Pending
-
2021
- 2021-09-23 JO JOP/2021/0260A patent/JOP20210260A1/ar unknown
- 2021-09-26 IL IL286727A patent/IL286727A/en unknown
-
2025
- 2025-12-04 JP JP2025230741A patent/JP2026048748A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210143878A (ko) | 2021-11-29 |
| PH12021552352A1 (en) | 2022-09-05 |
| JP2026048748A (ja) | 2026-03-17 |
| EP4548935A2 (en) | 2025-05-07 |
| EP3946340A1 (en) | 2022-02-09 |
| MA55486A (fr) | 2022-02-09 |
| BR112021019203A2 (pt) | 2021-11-30 |
| SG11202109854RA (en) | 2021-10-28 |
| WO2020201138A1 (en) | 2020-10-08 |
| MX2021011943A (es) | 2021-11-03 |
| CA3130773A1 (en) | 2020-10-08 |
| JOP20210260A1 (ar) | 2023-01-30 |
| AU2020253054B2 (en) | 2026-01-08 |
| CN113645975A (zh) | 2021-11-12 |
| EP4548935A3 (en) | 2025-08-06 |
| AU2020253054A1 (en) | 2021-09-30 |
| US20220175768A1 (en) | 2022-06-09 |
| JP2022527482A (ja) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286727A (en) | fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma | |
| IL279258B (en) | tyrosine kinase inhibitors | |
| SG11201607706SA (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
| EP3399968B8 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| EP3648753A4 (en) | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| IL283599A (en) | Tyrosine kinase inhibitors, preparations and methods | |
| EP3962908A4 (en) | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | |
| EP3448852A4 (en) | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL | |
| EP3226869A4 (en) | Kinase inhibitor prodrug for the treatment of cancer | |
| DK3972604T3 (da) | Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria | |
| EP3328496A4 (en) | Inhibitors of ack1/tnk2 tyrosine kinase | |
| MX393992B (es) | Compuestos de aminotiazol como inhibidores de la proteina quinasa | |
| EP4169918B8 (en) | Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer | |
| IL290798A (en) | Prodrugs of the tyrosine kinase inhibitor for treating cancer | |
| EP3999064A4 (en) | Inhibitors of tyrosine kinase | |
| SG10201909596RA (en) | Synthesis of Tyrosine Kinase Inhibitors | |
| MA55522A (fr) | Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial | |
| HK40068921A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| HK40068919A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| EP3923947A4 (en) | FGFR INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3774818A4 (en) | TYROSINE KINASE INHIBITORS FMS TYPE | |
| GB201807845D0 (en) | Kinase Inhibitors |